The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B

Clinical Infectious Diseases

Volumn 56, Issue 5, 2013, Pages 701-703

  Farmakiotis, Dimitrios ^a   Tverdek, Frank P ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adverse drug reactions; amphotericin B; infusion reactions

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DIPHENHYDRAMINE; HYDROCORTISONE; PARACETAMOL;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BRADYCARDIA; CHEMOPROPHYLAXIS; CHILD; CHILL; CLINICAL ARTICLE; CONFUSION; DISEASE SEVERITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HOSPITAL PATIENT; HUMAN; LOW BACK PAIN; MALE; MEDICAL RECORD REVIEW; MYALGIA; MYCOSIS; PRIORITY JOURNAL; SCHOOL CHILD; THORAX PAIN; TREMOR;

EID: 84873645296     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis972     Document Type: Article

References (9)

1. Dupont B. Overview of lipid formulations of amphotericin-B. J Antimicrob Chemother 2002; 49(Suppl 1):31-6.
2. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-18.
3. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155-63.
4. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-41.
6. Pearson AK, Kontoyiannis DP, Alexander B. Fungal infections in transplant and oncology patients. Hematol Oncol Clin N Am 2011; 25: 193-213.
7. Craddock C, Anson J, Chu P, et al. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex. Expert Opin Drug Saf 2010; 9:139-47.
8. Roden MM, Nelson LD, Knudsen DA, et al. Triad of acute infusionrelated reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003; 36:113-20.
9. O'Connor N, Borley A. Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex. Curr Med Res Opin 2009; 25:749-54.